Antidepressant Therapy (ADT)
Sponsors
Forest Laboratories, AbbVie
Conditions
Generalized Anxiety Disorder (GAD)Major Depressive Disorder
Phase 2
Phase 3
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
CompletedNCT01715805
Start: 2012-11-15End: 2016-06-24Updated: 2019-08-28
Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder
CompletedNCT01838876
Start: 2013-04-29End: 2015-07-27Updated: 2019-08-21
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
CompletedNCT03739203
Start: 2018-11-10End: 2021-09-06Updated: 2022-09-21